Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension study

Yoo, DH; Prodanovic, N; Jaworski, J; Miranda, P; Ramiterre, E; Lanzon, A; Baranauskaite, A; Wiland, P; Abud-Mendoza, C; Oparanov, B; Smiyan, S; Kim, H; Lee, SJ; Kim, S; Park, W

Yoo, DH (reprint author), Hanyang Univ Hosp Rheumat Dis, Div Rheumatol, 222-1 Wangsimni Ro, Seoul 04763, South Korea.; Park, W (reprint author), IN HA Univ, Sch Med Med Rheumatol, 366 Seohae Daero, Inchon 22332, South Korea.

ANNALS OF THE RHEUMATIC DISEASES, 2017; 76 (2): 355

Abstract

Objectives To assess the efficacy and safety of switching from the infliximab reference product (RP; Remicade) to its biosimilar CT-P13 (Remsima, Infl......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索